| Data set | Procedure | What's in this data set | Panel | Sex | Age (weeks) | Year |
|---|---|---|---|---|---|---|
|
|
body size and weight | Body weight, body length, body mass index. Aging study, 6mo, 12mo, 20mo. | inbred (32) | both | 26, 52, 87 wks | 2008 |
|
|
DXA | Body mass, fat mass, lean mass, bone mineral density and content, body area, bone area. Aging study, 6mo, 12mo, 20mo. | inbred (32) | both | 26, 52, 87 wks | 2008 |
|
|
body weight
with high-fat diet |
inbred w/CC8 | both | 8-21 wks | 2021 | |
|
|
glucose tolerance
with high-fat diet |
Plasma glucose levels: 0, 15, 30, 45, 60, 90, 120, 150, and 180 min, post oral gavage following overnight fast. | inbred w/CC8 | both | 8-21 wks | 2021 |
|
|
hormone quantification
with high-fat diet |
Insulin levels following glucose post oral gavage: 0, 15, 30 min. | inbred w/CC8 | both | 8-21 wks | 2021 |
|
|
intake monitoring
with high-fat diet |
Food intake. | inbred w/CC8 | both | 8-21 wks | 2021 |
|
|
lipid profile
with high-fat diet |
Cholesterol, HDL, LDL, triglycerides, free fatty acids. | inbred w/CC8 | both | 8-21 wks | 2021 |
|
|
metabolic panel
with high-fat diet |
Enzymes, creatinine, iron, lactate, urea. | inbred w/CC8 | both | 8-21 wks | 2021 |
|
|
monitoring system
with high-fat diet |
Oxygen consumption, carbon dioxide production, respiratory exchange rate (RER); activity. | inbred w/CC8 | both | 8-21 wks | 2021 |
|
|
organ dimensions
with high-fat diet |
Intestine length. | inbred w/CC8 | both | 8-21 wks | 2021 |
|
|
organ weights
with high-fat diet |
Cecum, muscles, heart, heart-atria, kidney, liver, spleen, fat pads. | inbred w/CC8 | both | 8-21 wks | 2021 |
|
|
treadmill endurance test
with high-fat diet |
Distance traveled. | inbred w/CC8 | both | 8-21 wks | 2021 |
|
|
genotype assessment | Gpr84 allele assessment. PCR, sequencing. | inbred w/CC8 (58) | both | 6wks | 2013 |
|
|
immune cell quantification | Regulatory T cells (Treg), thymus, spleen. | inbred (33) | m | 5-6wks | 2007 |
|
|
ventilator
with methacholine |
Airway resistance. Baseline vs. methacholine-challenged (several doses). | inbred (37) | both | 9-12wks | 2010 |
|
|
histopathology | Lung adenoma frequency and severity at 20mo. Tumor incidence, cancer, aging. | inbred (28) | both | 87wks | 2011 |
|
|
health assessment
with Plasmodium berghei |
Susceptibility, Plasmodium berghei (malaria). Parasitemia in blood and distribution in brain, spleen, lungs, liver. | inbred (31) | both | 8-12wks | 2010 |
|
|
genotyping | SNP profiling, 131,000+ genomic locations, 1-19,X. | inbred (89) | 2009 | ||
|
|
monitoring system
with morphine |
Induced respiratory depression, time to recovery (for mice that survived), survival data (for mice that did not survive). | inbred w/CC8 (8) | both | 8-24wks | 2020 |
|
|
genotyping | SNP profiling, 470,000+ genomic locations, 1-19,X,Y,MT. | inbred (142) | m | 2014 | |
|
|
body size and weight | Body weight and length. | inbred w/CC8 (72) | both | 10-13wks | 2009 |
|
|
complete blood count | Hematology. | inbred w/CC8 (72) | both | 10-13wks | 2009 |
|
|
DXA | Body mass, fat mass, lean mass, bone mineral density. | inbred w/CC8 (72) | both | 10-13wks | 2009 |
|
|
lipid profile | Cholesterol, HDL, triglycerides, free fatty acids. 4h fast, plasma. | inbred w/CC8 (72) | both | 10-13wks | 2009 |
|
|
metabolic panel | Clinical blood chemistry (plasma). 4h fast. | inbred w/CC8 (72) | both | 10-13wks | 2009 |
|
|
body weight | Body weight | CC diallel w/par (62) | both | 8-16wks | 2012 |
|
|
complete blood count | Hematology. | CC diallel w/par (62) | both | 8-16wks | 2012 |
|
|
DXA | Body mass, fat mass, lean mass, bone mineral density and content, bone area. | CC diallel w/par (62) | both | 8-16wks | 2012 |
|
|
ECG | Wave amplitudes and intervals. Conscious. | CC diallel w/par (62) | both | 8-16wks | 2012 |
|
|
lipid profile | Cholesterol, HDL, triglycerides. 4h fast, plasma. | CC diallel w/par (62) | both | 8-16wks | 2012 |
|
|
metabolic panel | Glucose (plasma). 4h fast. | CC diallel w/par (62) | both | 8-16wks | 2012 |
|
|
tail cuff | Heart rate and blood pressure. Conscious mice. | CC diallel w/par (62) | both | 8-16wks | 2012 |
|
|
immune cell quantification | Natural killer T cells in peripheral blood, spleen, thymus. | inbred (38) | both | 8-10wks | 2011 |
|
|
behavior observation | Wildness scoring. | CC diallel w/par (62) | both | 7-15wks | 2011 |
|
|
body size and weight | Body weight, body length, tail length. | CC diallel w/par (62) | both | 7-15wks | 2011 |
|
|
colony observation | Reproduction, fecundity. | CC diallel w/par (62) | both | 7-15wks | 2011 |
|
|
complete blood count | Hematology. | CC diallel w/par (62) | both | 7-15wks | 2011 |
|
|
fat pad weights | Gonadal fat pad weight. | CC diallel w/par (62) | both | 7-15wks | 2011 |
|
|
light-dark box | Anxiety, avoidance behavior. 10 min test. | CC diallel w/par (62) | both | 7-15wks | 2011 |
|
|
metabolic panel | Clinical blood chemistry. 16h fast. | CC diallel w/par (62) | both | 7-15wks | 2011 |
|
|
monitoring system | Sleep patterns. Dark period, total, peak activity. Baseline and after sleep deprivation. | CC diallel w/par (62) | both | 7-15wks | 2011 |
|
|
nociception assay | Hot plate and pressure on tail. | CC diallel w/par (62) | both | 7-15wks | 2011 |
|
|
open field test | Locomotor activity, exploratory, anxiety-related behavior. 10 min test. | CC diallel w/par (62) | both | 7-15wks | 2011 |
|
|
organ weights | Heart, kidney weights. | CC diallel w/par (62) | both | 7-15wks | 2011 |
|
|
behavior observation | Wildness scoring. | CC pre w/par (367) | both | 7-15wks | 2011 |
|
|
body size and weight | Body weight, tail length. | CC pre w/par (367) | both | 7-15wks | 2011 |
|
|
bone dimensions | Femur. | CC pre w/par (367) | both | 7-15wks | 2011 |
|
|
colony observation | Reproduction, fecundity. | CC pre w/par (367) | both | 7-15wks | 2011 |
|
|
complete blood count | Hematology. | CC pre w/par (367) | both | 7-15wks | 2011 |
|
|
fat pad weights | Gonadal fat pad weights. | CC pre w/par (367) | both | 7-15wks | 2011 |
|
|
light-dark box | Anxiety, avoidance behavior. 10 min test. | CC pre w/par (367) | both | 7-15wks | 2011 |
|
|
metabolic panel | Clinical blood chemistry. 16h fast. | CC pre w/par (367) | both | 7-15wks | 2011 |
|
|
monitoring system | Sleep patterns. Dark period, total, peak activity. Baseline and after sleep deprivation. | CC pre w/par (367) | both | 7-15wks | 2011 |
|
|
nociception assay | Hot plate and pressure on tail. | CC pre w/par (367) | both | 7-15wks | 2011 |
|
|
open field test | Locomotor activity, exploratory, anxiety-related behavior. 10 min test. | CC pre w/par (367) | both | 7-15wks | 2011 |
|
|
organ dimensions | Kidney length and volume. | CC pre w/par (367) | both | 7-15wks | 2011 |
|
|
organ weights | Heart, brain, kidney, spleen, gonadal fat pads, testicle weights. | CC pre w/par (367) | both | 7-15wks | 2011 |
|
|
body weight | Body weight | DO population w/par (9) | both | 12-16wks | 2013 |
|
|
light-dark box | Anxiety, avoidance behavior. 20 min test. | DO population w/par (9) | both | 12-16wks | 2013 |
|
|
nociception assay | Hot plate. | DO population w/par (9) | both | 12-16wks | 2013 |
|
|
open field test | Locomotor activity, exploratory, anxiety-related behavior. 20 min test. | DO population w/par (9) | both | 12-16wks | 2013 |
|
|
tail suspension test | Frequency climbing, time immobile, latency immobile. 5 min test. | DO population w/par (9) | both | 12-16wks | 2013 |
|
|
visual cliff | Anxiety, avoidance behavior. 20 min test. | DO population w/par (9) | both | 12-16wks | 2013 |
|
|
study archive | Intestinal microbiome study. | inbred (10) | both | 2012 | |
|
|
complete blood count | Hematology. | CC pre w/par (139) | m | 10-14wks | 2012 |
|
|
behavior observation
with haloperidol |
Observed involuntary repetitive movement. Baseline vs. during and after haloperidol 60d implant (several timepoints). | inbred w/CC8 (27) | m | 9-28wks | 2012 |
|
|
body weight
with haloperidol |
Baseline vs. after haloperidol 60d implant. | inbred w/CC8 (27) | m | 9-28wks | 2012 |
|
|
drug and metabolite quantification
with haloperidol |
Haloperidol concentration (plasma). Baseline vs. during and after haloperidol 60d implant (several timepoints). | inbred w/CC8 (27) | m | 9-28wks | 2012 |
|
|
inclined screen test
with haloperidol |
Baseline vs. during and after haloperidol 60d implant (several timepoints). | inbred w/CC8 (27) | m | 9-28wks | 2012 |
|
|
open field test
with haloperidol |
Locomotor activity, exploratory behavior, involuntary movement. Baseline vs. haloperidol 60d implant (several timepoints). 60 min test. | inbred w/CC8 (27) | m | 9-28wks | 2012 |
|
|
bottle choice test | Palatable food consumption, preference for Boost solution. | CC w/par (18) | both | 10-39wks | 2023 |
|
|
open field test | Locomotor response to novelty, habituation. | CC w/par (18) | both | 10-39wks | 2023 |
|
|
operant conditioning chamber | Reversal learning (impulsive action) and delay discounting (impulsive choice). | CC w/par (18) | both | 10-39wks | 2023 |
|
|
conditioned place preference test | In novel zone: exploration counts, entrance counts, time spent, activity counts, movement counts. | CC w/CC8 (61) | both | 4-25wks | 2021 |
|
|
hole board test | Number of entries, novel entries, and repeat entries. | CC w/CC8 (61) | both | 4-25wks | 2021 |
|
|
in vitro assay | Circadian parameters in fibroblast cultures: period, amplitude, phase, damping rate, goodness of fit. | CC w/CC8 (61) | both | 4-25wks | 2021 |
|
|
light-dark box | Distance traveled, ambulatory time and counts, resting time, stereotypic time and counts, jumping time and counts, vertical time and counts, time in light/dark. | CC w/CC8 (61) | both | 4-25wks | 2021 |
|
|
open field test
with cocaine |
Distance traveled, habituation ratio, number of rears, ambulatory time, time in perimeter, corners, and center; cocaine sensitization. | CC w/CC8 (61) | both | 4-25wks | 2021 |
|
|
operant conditioning chamber
with cocaine |
Number of infusions, active lever presses, inactive lever presses, intravenous self administration, reversal learning. | CC w/CC8 (61) | both | 4-25wks | 2021 |
|
|
in vitro assay
with Bacillus anthracis lethal toxin |
Bacillus anthracis lethal toxin (anthrax) susceptibility. | inbred (50) | f | 6-8wks* | 1998 |
|
|
urinalysis | Microalbumin, creatinine, ratio. | inbred w/CC7 (34) | m | 10wks | 2012 |
|
|
urinalysis | Microalbumin, creatinine, ratio. | CC pre w/par (163) | m | 10wks | 2012 |
|
|
body weight
with influenza A (H1N1) virus |
Body weight | CC pre w/par (163) | f | 8-16wks | 2012 |
|
|
health assessment
with influenza A (H1N1) virus |
Clinical health assessment score and strain susceptibility index 4 days after infection with influenza A (H1N1) virus. | CC pre w/par (163) | f | 8-16wks | 2012 |
|
|
histopathology
with influenza A (H1N1) virus |
Lungs and airway 4 days after infection with influenza A (H1N1) virus. | CC pre w/par (163) | f | 8-16wks | 2012 |
|
|
in vitro assay
with influenza A (H1N1) virus |
Viral replication log titer 4 days after infection with influenza A (H1N1) virus. In vitro. | CC pre w/par (163) | f | 8-16wks | 2012 |
|
|
open field test | Locomotor, exploratory, and anxiety-related behavior. 20 min test some at 5 min intervals. | inbred w/CC8 (8) | both | 8-9wks | 2020 |
|
|
grip strength | Several trials. | inbred w/CC8 (8) | both | 8-10wks | 2020 |
|
|
observation (SHIRPA) | Behavior, and neurosensory responses (SHIRPA protocol). | inbred w/CC8 (8) | both | 8-10wks | 2020 |
|
|
rotarod | Latency to fall from accelerating rotarod. | inbred w/CC7 (7) | both | 9-10wks | 2020 |
|
|
acoustic startle test | Acoustic startle response, prepulse inhibition. | inbred w/CC8 (8) | both | 9-10wks | 2020 |
|
|
lipid profile | Cholesterol, HDL, non-HDL, triglycerides, fatty acids. 16h fast, plasma. | inbred (5) | both | 10-11wks | 2020 |
|
|
metabolic panel | Glucose, glycerol. 16h fast. | inbred (5) | both | 10-11wks | 2020 |
|
|
nociception assay | Hot plate (two trials). | inbred w/CC8 (8) | both | 11-12wks | 2020 |
|
|
transepidermal water loss test | Transepidermal water loss in condenser chamber. | inbred w/CC8 (8) | both | 11-12wks | 2020 |
|
|
intake monitoring | Food, water intake. 21h test. | inbred w/CC8 (8) | both | 12-13wks | 2020 |
|
|
monitoring system | Locomotor activity and energy metabolism. 21h test. | inbred w/CC8 (8) | both | 12-13wks | 2020 |
|
|
NMR | Body mass, fat and lean tissue mass. | inbred w/CC8 (8) | both | 12-13, 18-19wks | 2020 |
|
|
glucose tolerance | 0 to 120 min after 20% glucose i.p., 16h fast. | inbred w/CC8 (6) | both | 13-14wks | 2020 |
|
|
echocardiography | Cardiovascular function and morphology. | inbred w/CC8 (8) | both | 14-15wks | 2020 |
|
|
ECG | Heart rate and wave intervals. Conscious. | inbred (6) | both | 14-15wks | 2020 |
|
|
computed tomography | Retinal thickness and fundus vessels. | inbred w/CC8 (8) | both | 14-17wks | 2020 |
|
|
organ dimensions | Axial length of eye. | inbred w/CC8 (8) | both | 14-17wks | 2020 |
|
|
Scheimpflug imaging | Eye lens density. | inbred w/CC8 (8) | both | 14-17wks | 2020 |
|
|
virtual optomotor | Threshold of spatial frequency. | inbred w/CC8 (8) | both | 14-17wks | 2020 |
|
|
complete blood count | Hematology. | inbred w/CC8 (8) | both | 20-21wks | 2020 |
|
|
lipid profile | Cholesterol, triglycerides. No fast, plasma. | inbred w/CC8 (8) | both | 16-17, 20-21wks | 2020 |
|
|
metabolic panel | Clinical blood chemistry (plasma). No fast. | inbred w/CC8 (8) | both | 16-17, 20-21wks | 2020 |
|
|
ABR test | Auditory brainstem response. | inbred w/CC7 (7) | both | 17-18wks | 2020 |
|
|
body size and weight | Body weight and length. | inbred w/CC8 (8) | both | 17-18wks | 2020 |
|
|
DXA | Body mass, fat mass, lean mass, bone mineral density and content, bone area. | inbred w/CC8 (8) | both | 17-18wks | 2020 |
|
|
X-ray | Lumbar vertebrae count. | inbred w/CC8 (8) | both | 17-18wks | 2020 |
|
|
ventilator | Lung, respiratory function. | inbred w/CC8 (8) | f | 21-22wks | 2020 |
|
|
autoantibody quantification | Anti-DNA autoantibodies, rheumatoid factor. | inbred w/CC8 (8) | both | 16-17, 20-21wks | 2020 |
|
|
immunoglobulin quantification | Immunoglobulins (plasma). | inbred w/CC8 (8) | both | 16-17, 20-21wks | 2020 |
|
|
bone dimensions | Tibia bone length. | inbred w/CC8 (8) | both | 20-21wks | 2020 |
|
|
organ weights | Heart, liver, spleen weights. | inbred w/CC8 (8) | both | 20-21wks | 2020 |
|
|
body weight | Body weight and growth curve from 8wks to 21wks. | inbred w/CC8 (8) | both | 8-21wks | 2020 |
|
|
histopathology | Kidney pathology at 20mo. | inbred (23) | both | 87wks | 2014 |
|
|
study archive | Exome genotype data. Fastq files. | inbred (6) | m | 2013 | |
|
|
urinalysis | Microalbumin, creatinine, ratio. Aging study, 6mo, 12mo, and 20mo. | inbred (30) | both | 52, 78, 104 wks | 2008 |
|
|
histopathology | Kidney pathology. Aging study, 6mo, 12mo, 20mo. | inbred (29) | m | 52, 78, 104 wks | 2013 |
|
|
body weight | Body weight | inbred w/CC8 (62) | both | 8-14wks | 2021 |
|
|
open field test | Locomotor activity and grooming behavior. | inbred w/CC8 (62) | both | 8-14wks | 2021 |
|
|
body size and weight | Body length measurements. | inbred w/CC8 (62) | both | 10-20 wks | 2021 |
|
|
gait analysis | Angular velocity, Stride speed, Step length, Step width, and other gait metrics. | inbred w/CC8 (62) | both | 10-20 wks | 2021 |
|
|
open field test | Distance traveled. | inbred w/CC8 (62) | both | 10-20 wks | 2021 |
|
|
immune cell quantification | Immunological cell variation. | CC w/par (76) | both | 5-8wks | 2018 |
|
|
body weight | Body weight | inbred (34) | both | 8wks | 2012 |
|
|
treadmill endurance test | Duration, distance, work. | inbred (34) | both | 8wks | 2012 |
|
|
body weight
with exercise |
Baseline vs. after exercise (access to running wheel). | CC pre w/par (184) | m | 10-12wks | 2011 |
|
|
intake monitoring
with exercise |
Caloric intake. Baseline vs. after exercise (access to running wheel). Metabolism, food intake. | CC pre w/par (184) | m | 10-12wks | 2011 |
|
|
monitoring system
with exercise |
Respiratory exchange ratio. Baseline (before access to running wheel). | CC pre w/par (184) | m | 10-12wks | 2011 |
|
|
MRI
with exercise |
Body composition (percent fat). Baseline vs. after exercise (access to running wheel). | CC pre w/par (184) | m | 10-12wks | 2011 |
|
|
running wheel monitoring
with exercise |
Distance, speed at days 1, 6, and 12. | CC pre w/par (184) | m | 10-12wks | 2011 |
|
|
apoptosis assessment | Aging study, 6mo, 12mo, 20mo. | inbred (30) | both | 26, 52, 87 wks | 2008 |
|
|
chromosome instability assessment | Chromosome instability. Aging study, 6mo, 12mo, 20mo. | inbred (30) | both | 26, 52, 87 wks | 2008 |
|
|
body weight
with high-fat diet and olanzapine |
Body weight and growth curve from age 8wks to 18wks weighed every 2wks. Olanzapine vs. control (both groups high-fat diet). | inbred w/CC8 (9) | f | 8-18wks | 2014 |
|
|
body weight | Body weight | inbred (8) | m | 10-66wks | 2015 |
|
|
histopathology | Male reproductive histopathology. Percent normal vs. abnormal sperm, seminiferous tubules. | inbred (8) | m | 10-66wks | 2015 |
|
|
metabolic panel | Male reproductive sperm lactate production. | inbred (8) | m | 10-66wks | 2015 |
|
|
organ weights | Male reproductive organ weights. Testes, seminal vesicles, epididymis, vas deferens. | inbred (8) | m | 10-66wks | 2015 |
|
|
sperm count | Sperm count. Hemocytometer. | inbred (8) | m | 10-66wks | 2015 |
|
|
microscopy | Male reproductive sperm motility. | inbred w/CC8 (8) | m | 10-66wks | 2015 |
|
|
complete blood count | Hematology. Aging study, 6mo, 12mo, 18mo, 24mo. | inbred (30) | both | 26, 52, 78, 104 wks | 2007 |
|
|
complete blood count | Hematology. Aging study, 6mo, 12mo, 18mo, 24mo. | inbred (32) | both | 26, 52, 78, 104 wks | 2007 |
|
|
immune cell quantification | Aging study, 6mo, 12mo, 18mo, 24mo. | inbred (32) | both | 26, 52, 78, 104 wks | 2007 |
|
|
body weight | Body weight | inbred (32) | m | 7-9wks | 2007 |
|
|
hormone quantification | Corticosterone (serum). | inbred (32) | m | 7-9wks | 2007 |
|
|
open field test | Locomotor and anxiety-related behavior. 10 min test. | inbred (32) | m | 7-9wks | 2007 |
|
|
tail suspension test | Immobility percentage. | inbred (32) | m | 7-9wks | 2007 |
|
|
in vitro assay
with Neisseria musculi |
Bacterial load after inoculation with Neisseria musculi. Oral cavity. | inbred w/CC8 (8) | both | 8-16wks | 2018 |
|
|
genotyping | SNP profiling, 80,000,000+ genomic locations. SNPs and indels. 1-19,X. | inbred (37) | both | 2017 | |
|
|
body weight
with influenza A (H3N2) virus |
Influenza A (H3N2) virus (several doses) vs. baseline. Several timepoints. | inbred w/CC8 (8) | both | 7-13wks | 2013 |
|
|
health assessment
with influenza A (H3N2) virus |
Survival rate, susceptibility, influenza A (H3N2) virus (several doses). | inbred w/CC8 (8) | both | 7-13wks | 2013 |
|
|
body weight
with influenza A (H3N2) virus |
Influenza A (H3N2) virus vs. controls. Several timepoints. | inbred w/CC8 (8) | f | 8-12wks | 2016 |
|
|
complete blood count
with influenza A (H3N2) virus |
White blood cell count and differentials. Influenza A (H3N2) virus vs. controls. | inbred w/CC8 (8) | f | 8-12wks | 2016 |
|
|
in vitro assay
with influenza A (H3N2) virus |
Viral load in lungs after infection with influenza A (H3N2) virus. | inbred w/CC8 (8) | f | 8-12wks | 2016 |
|
|
body weight
with influenza A (H3N2) virus |
Influenza A (H3N2) virus vs. controls. Several timepoints. | inbred w/CC8 (8) | f | 8-12wks | 2016 |
|
|
organ weights
with influenza A (H3N2) virus |
Lung weight. Animals infected with influenza A (H3N2) virus vs. controls. | inbred w/CC8 (8) | f | 8-12wks | 2016 |
|
|
gait analysis | Aging study, 6mo, 18mo. | inbred (32) | both | 26, 52, 78, 104 wks | 2008 |
|
|
grip strength | Peak tension. 3 trials. Aging study, 6mo, 12mo, 18mo, 24mo. | inbred (32) | both | 26, 52, 78, 104 wks | 2008 |
|
|
colony observation | Litter size assessment. | CC diallel w/par (62) | f | 3wks | 2018 |
|
|
tail cuff | Heart rate and blood pressure. Conscious mice. | inbred (25) | m | 10wks | 2007 |
|
|
body weight
with selenium |
Body weight curve 3 to 12 wks, control group. | inbred w/CC8 (8) | m | 3-14wks | 2018 |
|
|
RNA expression profiling
with selenium |
Selenium regulation of selenoprotein enzyme activity and transcripts. | inbred w/CC8 (8) | m | 3-14wks | 2018 |
|
|
body weight
with cocaine |
Body weight | inbred (45) | m | 8-11wks | 2015 |
|
|
open field test
with cocaine |
Locomotor activity. Baseline (saline) vs. cocaine 20 mg/kg i.p. 30 min test. | inbred (45) | m | 8-11wks | 2015 |
|
|
forced swim test
with ovariectomy |
Mice with ovariectomy surgery vs. controls (sham surgery), 6 min test. | inbred (37) | f | 8-10wks | 2016 |
|
|
open field test
with ovariectomy |
Locomotor activity and exploratory behavior. Mice with ovariectomy surgery vs. controls (sham surgery), 10 min test. | inbred (37) | f | 8-10wks | 2016 |
|
|
biomarker quantification
with acetaminophen |
Liver cytochrome isoforms. Acetaminophen vs. control. 18h fast. | inbred w/CC7 (37) | m | 8-17wks | 2005 |
|
|
histopathology
with acetaminophen |
Liver histopathology, necrosis after acetaminophen vs. control. 18h fast. | inbred w/CC7 (37) | m | 8-17wks | 2005 |
|
|
metabolic panel
with acetaminophen |
Blood urea nitrogen, alanine transaminase, aspartate transaminase (serum), liver enzyme homeostasis. Acetaminophen (several doses) vs. control, several timepoints post-Rx. 18h fast. | inbred w/CC7 (37) | m | 8-17wks | 2005 |
|
|
metabolite quantification
with acetaminophen |
Liver protein homeostasis. Acetaminophen vs. control. 18h fast. | inbred w/CC7 (37) | m | 8-17wks | 2005 |
|
|
organ weights
with acetaminophen |
Liver weight after acetaminophen (several doses) vs. control. 18h fast. | inbred w/CC7 (37) | m | 8-17wks | 2005 |
|
|
genotyping | SNP profiling, 132,000+ genomic locations, 1-19,X | HMDP (248) | both | 2018 | |
|
|
genotyping | SNP profiling, 130,000+ genomic locations, 1-19,X,Y,MT. | CC w/par (77) | m | 2020 | |
|
|
genotyping | SNP profiling, 76,000+ genomic locations, 1-19,X,MT | CC w/par (77) | both | 2017 | |
|
|
elevated plus maze | Locomotor activity. | inbred (38) | both | 12-14wks | 2010 |
|
|
light-dark box | Light-dark test. Anxiety-related behavior. | inbred (38) | both | 12-14wks | 2010 |
|
|
open field test | Locomotor activity. | inbred (38) | both | 12-14wks | 2010 |
|
|
immune cell quantification
with BEZ235, doxorubicin, idarubicin, selumetinib |
In vitro study of 4 cancer chemotherapies (BEZ235, doxorubicin, idarubicin, selumetinib) vs. control. Effect on immune cells. Normalized data. | inbred w/CC7 (36) | m | 10wks | 2015 |
|
|
ECG | Heart rate and wave intervals. Conscious. Aging study, 6mo, 12mo, 20mo. | inbred (29) | both | 26, 52, 87 wks | 2008 |
|
|
gait analysis | Aging study, 6mo, 12mo, 18mo. | inbred (31) | both | 26, 52, 78 wks | 2010 |
|
|
body weight | Aging study, 6mo, 12mo, and 18mo. | inbred (33) | both | 26, 52, 78 wks | 2007 |
|
|
hormone quantification | Insulin-like growth factor 1 (serum). Aging study, 6mo, 12mo, and 18mo. | inbred (33) | both | 26, 52, 78 wks | 2007 |
|
|
colony observation | Life span study. Survival curves. Aging study. | inbred (31) | both | max lifespan | 2007 |
|
|
lipid profile | Cholesterol (HDL). Aging study, 6mo, 12mo, 18mo. 4h fast, plasma. | inbred (32) | both | 26, 52, 78 wks | 2008 |
|
|
metabolic panel | Clinical blood chemistry. Aging study, 6mo, 12mo, 18mo. | inbred (32) | both | 26, 52, 78 wks | 2008 |
|
|
tympanometry | Middle ear function. | inbred (61) | both | 15-51d | 2008 |
|
|
body weight | inbred (30) | both | 7-15 wks | 2020 | |
|
|
intake monitoring | Food and water intake; 2-day test, second day data analyzed during 12:12h light and dark periods. | inbred (30) | both | 7-15 wks | 2020 |
|
|
monitoring system | Voluntary activity and energy expenditure. 2-day test, second day data analyzed during 12:12h light and dark periods. | inbred (30) | both | 7-15 wks | 2020 |